Multifunctional HBc Virus-Like Particles Reprogram Immunosuppressive Macrophages and Potentiate CD8+ T Cell Responses for Enhanced Cancer Immunotherapy
This HBc VLP-based nanovaccine constitutes a pioneering multifunctional platform designed to overcome TAM-mediated immunosuppression through synergistic integration of three modalities: antigen presentation, TAM phenotype reprogramming, and B7-H3 checkpoint blockade. To the best of our knowledge, this is the first nanovaccine architecture to enable coordinated immunomodulation. Its modular design supports the clinical translation of solid tumors and personalized immunotherapy.
Authors
- Keyue Wang
- Lianyan Wang (ORCID: https://orcid.org/0000-0002-4421-0128)
- Shuntao Liang (ORCID: https://orcid.org/0000-0003-2219-2683)
- Yongjie Chi
- Kai Zhao (ORCID: https://orcid.org/0000-0001-6139-1912)
- Xiaoxuan Yin (ORCID: https://orcid.org/0009-0009-2626-1667)
- Juan Ma (ORCID: https://orcid.org/0009-0008-1423-586X)
- Li Ma (ORCID: https://orcid.org/0000-0002-5444-5262)
- Zhu Yang
- Xin Xue (ORCID: https://orcid.org/0009-0002-3613-1507)
- Shou-Cheng Wang
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- China-Japan Friendship Hospital (CN)
- Institute of Process Engineering (CN)
- China Academy of Chinese Medical Sciences (CN)
- Beijing Friendship Hospital (CN)
- Beijing Shijitan Hospital (CN)
- University of Chinese Academy of Sciences (CN)
- Taizhou University (CN)
Publication Details
- Journal
- International Journal of Nanomedicine
- Published
- 2025-10-01
- DOI
- https://doi.org/10.2147/ijn.s548334
- Citations
- 3
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.06